| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.5 | 2.8 | 1.5 |
| Other income | 6.8 | 2.8 | 1.2 |
| Total income | 8.3 | 5.6 | 2.7 |
| Profit before exceptional items & tax | -45.6 | -101.9 | -43.9 |
| Profit before tax | -45.6 | -101.9 | -43.9 |
| Net profit | -45.6 | -101.9 | -43.9 |
| Operating margin | -549.4% | n/m | n/m |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +0.00% |
|---|
Source
Read the filing ↗
NSE results filing, NSE: SUVEN. Figures extracted from the filing.
Suven Life Sciences Ltd: key numbers
- Share price
- ₹335.00
- Market cap
- ₹9,466 Cr
- Revenue (annual)
- ₹7.11 Cr
- Net profit (annual)
- ₹-276.3 Cr
- P/E (TTM)
- -26.9×Sector 57.8×
- Promoter holding
- 65.47%-4.68% QoQ
- FII holding
- 0.48%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suven Life Sciences Ltd
All →
11:56 IST
NSE
Business Update
Suven Life Sciences Business Update
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
- clinical trial enrollment
- 424.0 patients
12:47 IST
NSE
Financial Results
Suven Life Sciences Q1 FY27 Results: Net Loss of ₹127.6 Cr, Loss Widens
Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹127.6 Cr